دورية أكاديمية
أعرض في EDS

Treatment with IgM-enriched intravenous immunoglobulins enhances clearance of stroke-associated bacterial lung infection.

التفاصيل البيبلوغرافية
العنوان: Treatment with IgM-enriched intravenous immunoglobulins enhances clearance of stroke-associated bacterial lung infection.
المؤلفون: McCulloch L; Centre for Inflammation Research, Institute for Regeneration and Repair, University of Edinburgh, Edinburgh, UK., Harris AJ; UK Dementia Research Institute, University of Edinburgh, Edinburgh, UK., Malbon A; Easter Bush Pathology, The Royal (Dick) School of Veterinary Studies and The Roslin Institute, University of Edinburgh, Edinburgh, UK., Daniels MJD; UK Dementia Research Institute, University of Edinburgh, Edinburgh, UK., Younas M; Division of Neuroscience and Experimental Psychology, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.; Geoffrey Jefferson Brain Research Centre, Manchester Academic Health Science Centre, Northern Care Alliance NHS Group, University of Manchester, Manchester, UK., Grainger JR; Geoffrey Jefferson Brain Research Centre, Manchester Academic Health Science Centre, Northern Care Alliance NHS Group, University of Manchester, Manchester, UK.; Lydia Becker Institute of Immunology and Inflammation, Division of Immunology, Immunity to Infection and Respiratory Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK., Allan SM; Division of Neuroscience and Experimental Psychology, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.; Geoffrey Jefferson Brain Research Centre, Manchester Academic Health Science Centre, Northern Care Alliance NHS Group, University of Manchester, Manchester, UK., Smith CJ; Geoffrey Jefferson Brain Research Centre, Manchester Academic Health Science Centre, Northern Care Alliance NHS Group, University of Manchester, Manchester, UK.; Greater Manchester Comprehensive Stroke Centre, Manchester Centre for Clinical Neurosciences, Manchester Academic Health Science Centre, Salford Royal NHS Foundation Trust, Salford, UK.; Division of Cardiovascular Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK., McColl BW; UK Dementia Research Institute, University of Edinburgh, Edinburgh, UK.
المصدر: Immunology [Immunology] 2022 Dec; Vol. 167 (4), pp. 558-575. Date of Electronic Publication: 2022 Aug 09.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Blackwell Scientific Publications Country of Publication: England NLM ID: 0374672 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2567 (Electronic) Linking ISSN: 00192805 NLM ISO Abbreviation: Immunology Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Oxford : Blackwell Scientific Publications
مواضيع طبية MeSH: Bacterial Infections* , Stroke*/complications , Stroke*/therapy, Mice ; Animals ; Immunoglobulins, Intravenous/therapeutic use ; Immunologic Factors ; Immunoglobulin M ; Bacteria ; Lung
مستخلص: Post-stroke infection is a common complication of stroke that is associated with poor outcome. We previously reported that stroke induces an ablation of multiple sub-populations of B cells and reduces levels of immunoglobulin M (IgM) antibody, which coincides with the development of spontaneous bacterial pneumonia. The loss of IgM after stroke could be an important determinant of infection susceptibility and highlights this pathway as a target for intervention. We treated mice with a replacement dose of IgM-enriched intravenous immunoglobulin (IgM-IVIg) prior to and 24 h after middle cerebral artery occlusion (MCAO) and allowed them to recover for 2- or 5-day post-surgery. Treatment with IgM-IVIg enhanced bacterial clearance from the lung after MCAO and improved lung pathology but did not impact brain infarct volume. IgM-IVIg treatment induced immunomodulatory effects systemically, including rescue of splenic plasma B cell numbers and endogenous mouse IgM and IgA circulating immunoglobulin concentrations that were reduced by MCAO. Treatment attenuated MCAO-induced elevation of selected pro-inflammatory cytokines in the lung. IgM-IVIg treatment did not increase the number of lung mononuclear phagocytes or directly modulate macrophage phagocytic capacity but enhanced phagocytosis of Staphylococcus aureus bioparticles in vitro. Low-dose IgM-IVIg contributes to increased clearance of spontaneous lung bacteria after MCAO likely via increasing availability of antibody in the lung to enhance opsonophagocytic activity. Immunomodulatory effects of IgM-IVIg treatment may also contribute to reduced levels of damage in the lung after MCAO. IgM-IVIg shows promise as an antibacterial and immunomodulatory agent to use in the treatment of post-stroke infection.
(© 2022 The Authors. Immunology published by John Wiley & Sons Ltd.)
References: Patel A, Berdunov V, King D, Quayyum Z, Wittenberg R, Knapp M. Executive summary Part 2: burden of Stroke in the next 20 years and potential returns from increased spending on research. London: Stroke Association; 2017.
Stroke Association. State of the Nation: Stroke statistics; 2018.
Bowen A, Patchick P. Cognitive rehabilitation and recovery after stroke. Behavioural consequences of stroke. New York: Springer-Verlag; 2014.
Adamson J, Beswick A, Ebrahim S. Is stroke the most common cause of disability? J Stroke Cerebrovasc Dis. 2004;13:171-7.
Westendorp W, Nederkoorn PJ, Vermeij JD, Dijkgraaf MG, de Beek D. Post-stroke infection: a systematic review and meta-analysis. BMC Neurol. 2011;11(1):110.
Aslanyan S, Weir CJ, Diener HC, Kaste M, Lees KR, the GAIN International Steering Committee and Investigators. Pneumonia and urinary tract infection after acute ischaemic stroke: a tertiary analysis of the GAIN international trial. Eur J Neurol. 2004;11(1):49-53.
Learoyd AE, Woodhouse L, Shaw L, Sprigg N, Bereczki D, Berge E, et al. Infections up to 76 days after stroke increase disability and death. Transl Stroke Res. 2017;8:541-8.
Elkind MSV, Boehme AK, Smith CJ, Meisel A, Buckwalter MS. Infection as a stroke risk factor and determinant of outcome after stroke. Stroke. 2020;51(10):3156-68.
Stroke Association. The stroke priority setting partnership results for investment. London: Stroke Association; 2021.
Vogelgesang A, Grunwald U, Langner S̈, Jack R, Bröker BM, Kessler C, et al. Analysis of lymphocyte subsets in patients with stroke and their influence on infection after stroke. Stroke. 2008;39:237-41.
Haeusler KG, Schmidt WUH, Föhring F, Meisel C, Helms T, Jungehulsing GJ, et al. Cellular immunodepression preceding infectious complications after acute ischemic stroke in humans. Cerebrovasc Dis. 2008;25(1-2):50-8.
McCulloch L, Smith CJ, McColl BW. Adrenergic-mediated loss of splenic marginal zone B cells contributes to infection susceptibility after stroke. Nat Commun. 2017;8:15051.
McCulloch L, Allan SM, Smith CJ, McColl BW. Interleukin-1 receptor antagonist treatment in acute ischaemic stroke does not alter systemic markers of anti-microbial defence. F1000Res. 2019;10(8):1039. https://doi.org/10.12688/f1000research.19308.2.
Martin F, Oliver AM, Kearney JF. Marginal zone and B1 B cells unite in the early response against T-independent blood-borne particulate antigens. Immunity. 2001;14(5):617-29.
Zouali M, Richard Y. Marginal zone B-cells, a gatekeeper of innate immunity. Front Immunol. 2011;2:63.
Kishore AK, Vail A, Jeans AR, Chamorro A, di Napoli M, Kalra L, et al. Microbiological etiologies of pneumonia complicating stroke. A systematic review. Stroke. 2018;49(7):1602-9.
Wood P, Stanworth S, Burton J, Jones A, Peckham DG, Green T, et al. Recognition, clinical diagnosis and management of patients with primary antibody deficiencies: a systematic review. Clin Exp Immunol. 2007;149(3):410-23.
Kaveri SV, Lacroix-Desmazes S, Bayry J. The antiinflammatory IgG. N Engl J Med. 2008;359(3):307-9.
Siberil S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, et al. Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective. Ann N Y Acad Sci. 2007;1110:497-506.
Nimmerjahn F, Ravetch JV. Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol. 2008;26(1):513-33.
Ehrenstein MR, Notley CA. The importance of natural IgM: scavenger, protector and regulator. Nat Rev Immunol. 2010;10(11):778-86.
Garbett ND, Munro CS, Cole PJ. Opsonic activity of a new intravenous immunoglobulin preparation: pentaglobin compared with sandoglobulin. Clin Exp Immunol. 1989;76(1):8-12.
McCabe WR, DeMaria A, Berberich H, Johns MA. Immunization with rough mutants of Salmonella minnesota: protective activity of IgM and IgG antibody to the R595 (Re chemotype) mutant. J Infect Dis. 1988;158(2):291-300.
Li J, Chen T, Yuan C, Zhao G, xu M, Li X, et al. Effect of intravenous immunoglobulin on the function of Treg cells derived from immunosuppressed mice with Pseudomonas aeruginosa pneumonia. PLoS One. 2017;12(5):e0176843.
Diep BA, le VT, Badiou C, le HN, Pinheiro MG, Duong AH, et al. IVIG-mediated protection against necrotizing pneumonia caused by MRSA. Sci Transl Med. 2016;8(357):357ra124.
Lachmann RA, Kaam AHLC, Haitsma JJ, Verbrugge SJC, Delreu F, Lachmann B. Immunoglobulin M-enriched intravenous polyclonal immunoglobulins reduce bacteremia following Klebsiella pneumoniae infection in an acute respiratory distress syndrome rat model. Exp Lung Res. 2004;30(4):251-60.
Rossmann FS, Kropec A, Laverde D, Saaverda FR, Wobser D, Huebner J. In vitro and in vivo activity of hyperimmune globulin preparations against multiresistant nosocomial pathogens. Infection. 2015;43(2):169-75.
RA, Rello J, Neira J, Maskin B, Ceraso D, Vasta L, et al. Effects of high-dose of intravenous immunoglobulin and antibiotics on survival for severe sepsis undergoing surgery. Shock. 2005;23(4):298-304.
Tugrul S, Ozcan PE, Akinci O, Seyhun Y, Cagatay A, Cakar N, et al. The effects of IgM-enriched immunoglobulin preparations in patients with severe sepsis [ISRCTN28863830]. Crit Care. 2002;6(4):357-62.
Welte T, Dellinger RP, Ebelt H, Ferrer M, Opal SM, Singer M, et al. Efficacy and safety of trimodulin, a novel polyclonal antibody preparation, in patients with severe community-acquired pneumonia: a randomized, placebo-controlled, double-blind, multicenter, phase II trial (CIGMA study). Intensive Care Med. 2018;44(4):438-48.
Percie du Sert N, Hurst V, Ahluwalia A, Alam S, Avey MT, Baker M, et al. The ARRIVE guidelines 2.0: updated guidelines for reporting animal research. J Cereb Blood Flow Metab. 2020;40(9):1769-77.
Percie du Sert N, Alfieri A, Allan SM, Carswell HVO, Deuchar GA, Farr TD, et al. The IMPROVE guidelines (ischaemia models: procedural refinements of in vivo experiments). J Cereb Blood Flow Metab. 2017;37(11):3488-517.
Osborne KA, Shigeno T, Balarsky AM, Ford I, McCulloch J, Teasdale GM, et al. Quantitative assessment of early brain damage in a rat model of focal cerebral ischaemia. J Neurol Neurosurg Psychiatry. 1987;50(4):402-10.
Katzan IL, Cebul RD, Husak SH, Dawson NV, Baker DW. The effect of pneumonia on mortality among patients hospitalized for acute stroke. Neurology. 2003;60(4):620-5.
Kandatsu N, Nan YS, Feng GG, Nishiwaki K, Hirokawa M, Ishikawa K, et al. Opposing effects of isoflurane and sevoflurane on neurogenic pulmonary edema development in an animal model. Anesthesiology. 2005;102(6):1182-9.
Nguyen TTT, Graf BA, Randall TD, Baumgarth N. sIgM-FcμR interactions regulate early B cell activation and plasma cell development after influenza virus infection. J Immunol. 2017;199(5):1635-46.
Baumgarth N, Herman OC, Jager GC, Brown LE, Herzenberg LA, Chen J. B-1 and B-2 cell-derived immunoglobulin M antibodies are nonredundant components of the protective response to influenza virus infection. J Exp Med. 2000;192(2):271-80.
Lu LL, Suscovich TJ, Fortune SM, Alter G. Beyond binding: antibody effector functions in infectious diseases. Nat Rev Immunol. 2018;18(1):46-61.
Liegeois M, Legrand C, Desmet CJ, Marichal T, Bureau F. The interstitial macrophage: a long-neglected piece in the puzzle of lung immunity. Cell Immunol. 2018;330:91-6.
Guilliams M, Bruhns P, Saeys Y, Hammad H, Lambrecht BN. The function of Fcγ receptors in dendritic cells and macrophages. Nat Rev Immunol. 2014;14(2):94-108.
Nagelkerke SQ, Dekkers G, Kustiawan I, van de Bovenkamp FS, Geissler J, Plomp R, et al. Inhibition of FcγR-mediated phagocytosis by IVIg is independent of IgG-Fc sialylation and FcγRIIb in human macrophages. Blood. 2014;124(25):3709-18.
Smith CJ, Kishore AK, Vail A, Chamorro A, Garau J, Hopkins SJ, et al. Diagnosis of stroke-associated pneumonia: recommendations from the pneumonia in stroke consensus group. Stroke. 2015;46(8):2335-40.
Ji R, Wang D, Shen H, Pan Y, Liu G, Wang P, et al. Interrelationship among common medical complications after acute stroke: pneumonia plays an important role. Stroke. 2013;44(12):3436-44.
Kalra L, Irshad S, Hodsoll J, Simpson M, Gulliford M, Smithard D, et al. Prophylactic antibiotics after acute stroke for reducing pneumonia in patients with dysphagia (STROKE-INF): a prospective, cluster-randomised, open-label, masked endpoint, controlled clinical trial. Lancet. 2015;386(10006):1835-44.
Westendorp WF, Vermeij JD, Zock E, Hooijenga IJ, Kruyt ND, Bosboom HJLW, et al. The Preventive Antibiotics in Stroke Study (PASS): a pragmatic randomised open-label masked endpoint clinical trial. Lancet. 2015;385(9977):1519-26.
Prass K, Meisel C, Höflich C, Braun J, Halle E, Wolf T, et al. Stroke-induced immunodeficiency promotes spontaneous bacterial infections and is mediated by sympathetic activation reversal by poststroke T helper cell type 1-like immunostimulation. J Exp Med. 2003;198:725-36.
Liesz A, Suri-Payer E, Veltkamp C, Doerr H, Sommer C, Rivest S, et al. Regulatory T cells are key cerebroprotective immunomodulators in acute experimental stroke. Nat Med. 2009;15(2):192-9.
Offner H, Subramanian S, Parker SM, Wang C, Afentoulis ME, Lewis A, et al. Splenic atrophy in experimental stroke is accompanied by increased regulatory T cells and circulating macrophages. J Immunol. 2006;176(11):6523-31.
Brait VH, Arumugam TV, Drummond GR, Sobey CG. Importance of T lymphocytes in brain injury, immunodeficiency, and recovery after cerebral ischemia. J Cereb Blood Flow Metab. 2012;32(4):598-611.
Wong CHY, Jenne CN, Lee WY, Léger C, Kubes P. Functional innervation of hepatic iNKT cells is immunosuppressive following stroke. Science. 2011;334(6052):101-5.
Hoffmann S, Harms H, Ulm L, Nabavi DG, Mackert BM, Schmehl I, et al. Stroke-induced immunodepression and dysphagia independently predict stroke-associated pneumonia-the PREDICT study. J Cereb Blood Flow Metab. 2016;37:3671-82.
Urra X, Cervera A, Obach V, Climent N, Planas AM, Chamorro A. Monocytes are major players in the prognosis and risk of infection after acute stroke. Stroke. 2009;40(4):1262-8.
Romer C, Engel O, Winek K, Hochmeister S, Zhang T, Royl G, et al. Blocking stroke-induced immunodeficiency increases CNS antigen-specific autoreactivity but does not worsen functional outcome after experimental stroke. J Neurosci. 2015;35(20):7777-94.
Anrather J, Iadecola C. Inflammation and stroke: an overview. Neurotherapeutics. 2016;13(4):661-70.
Schroeder HW Jr, Cavacini L. Structure and function of immunoglobulins. J Allergy Clin Immunol. 2010;125(2 Suppl 2):S41-52.
Klimovich VB. IgM and its receptors: structural and functional aspects. Biochemistry (Moscow). 2011;76(5):534-49.
Chovancova Z, Kralickova P, Pejchalova A, Bloomfield M, Nechvatalova J, Vlkova M, et al. Selective IgM deficiency: clinical and laboratory features of 17 patients and a review of the literature. J Clin Immunol. 2017;37(6):559-74.
Hodkinson JP, Bangs C, Wartenberg-Demand A, Bauhofer A, Langohr P, Buckland MS, et al. Low IgA and IgM is associated with a higher prevalence of bronchiectasis in primary antibody deficiency. J Clin Immunol. 2017;37(4):329-31.
Armstrong JR, Mosher BD. Aspiration pneumonia after stroke: intervention and prevention. Neurohospitalist. 2011;1(2):85-93.
Arumugam TV, Tang SC, Lathia JD, Cheng A, Mughal MR, Chigurupati S, et al. Intravenous immunoglobulin (IVIG) protects the brain against experimental stroke by preventing complement-mediated neuronal cell death. Proc Natl Acad Sci U S A. 2007;104(35):14104-9.
Walberer M, Nedelmann M, Ritschel N, Mueller C, Tschernatsch M, Stolz E, et al. Intravenous immunoglobulin reduces infarct volume but not edema formation in acute stroke. Neuroimmunomodulation. 2010;17(2):97-102.
Yang-Wei Fann D, Lee SY, Manzanero S, Tang SC, Gelderblom M, Chunduri P, et al. Intravenous immunoglobulin suppresses NLRP1 and NLRP3 inflammasome-mediated neuronal death in ischemic stroke. Cell Death Dis. 2013;4(9):e790.
Tunik S, Aluclu MU, Acar A, Akkoc H, Guzel A, Alabalik U, et al. The effects of intravenous immunoglobulin on cerebral ischemia in rats: an experimental study. Toxicol Ind Health. 2013;32(2):229-34.
Lok KZ, Basta M, Manzanero S, Arumugam TV. Intravenous immunoglobulin (IVIg) dampens neuronal toll-like receptor-mediated responses in ischemia. J Neuroinflammation. 2015;12:73-3.
Chen X, Arumugam TV, Cheng YL, Lee JH, Chigurupati S, Mattson MP, et al. Combination therapy with low-dose IVIG and a C1-esterase inhibitor ameliorates brain damage and functional deficits in experimental ischemic stroke. Neuromolecular Med. 2018;20(1):63-72.
Dalakas MC, Clark WM. Strokes, thromboembolic events, and IVIg: rare incidents blemish an excellent safety record. Neurology. 2003;60(11):1736-7.
Bayry J, Fournier EM, Maddur MS, Vani J, Wootla B, Sibéril S, et al. Intravenous immunoglobulin induces proliferation and immunoglobulin synthesis from B cells of patients with common variable immunodeficiency: a mechanism underlying the beneficial effect of IVIg in primary immunodeficiencies. J Autoimmun. 2011;36(1):9-15.
Stephan W. Elimination of complement fixation of gamma-globulin by chemical modification with beta-propiolactone. Z Klin Chem Klin Biochem. 1969;7(3):282-6.
Jungi TW, Santer M, Lerch PG, Barandun S. Effect of various treatments of gamma-globulin (IgG) for achieving intravenous tolerance on the capacity to interact with human monocyte Fc receptors. A comparative study. Vox Sang. 1986;51(1):18-26.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet (London, England). 2020;395(10223):497-506.
Bonaventura A, Vecchié A, Wang TS, Lee E, Cremer PC, Carey B, et al. Targeting GM-CSF in COVID-19 pneumonia: rationale and strategies. Front Immunol. 2020;11:1625-5.
معلومات مُعتمدة: MR/R001316/1 United Kingdom Medical Research Council; 220755/Z/20/Z United Kingdom Wellcome Trust
فهرسة مساهمة: Keywords: B cell; immune suppression; intravenous immunoglobulins; macrophage; pneumonia; stroke
المشرفين على المادة: 0 (Immunoglobulins, Intravenous)
0 (Immunologic Factors)
0 (Immunoglobulin M)
تواريخ الأحداث: Date Created: 20220726 Date Completed: 20221128 Latest Revision: 20221215
رمز التحديث: 20231215
DOI: 10.1111/imm.13553
PMID: 35881080
قاعدة البيانات: MEDLINE
الوصف
تدمد:1365-2567
DOI:10.1111/imm.13553